Close menu




June 22nd, 2022 | 12:32 CEST

Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech

  • Biotechnology
Photo credits: pixabay.com

When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.

time to read: 3 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , NERVGEN PHARMA CORP | CA64082X2032 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Valneva: How far will the recovery go?

    The Valneva share has not performed well this year and lost around 40% over three months. Recently, however, the entry of Pfizer caused a small price fireworks. The pharmaceutical giant secured a stake of about 8% in Valneva and intends to push its Lyme vaccine candidate VLA15 in particular. Analysts at Bryan Garnier believe a complete takeover is even possible. The experts at Oddo BHF see the situation differently. According to them, the Corona vaccine situation dominates the equity story around Valneva.

    However, there is also positive news around the Corona vaccine. The European Medicines Agency (EMA) has accepted the marketing authorization application for the VLA2001 Corona vaccine. Nevertheless, rumors are weighing on the market that the EU's letter of intent to acquire the vaccine may be cancelled. Looking at the recent share price rally in the light of the month-long sell-off, Valneva may now be entering a bear market rally. It will probably take some time before the share enters favourable waters.

    NervGen: MS and Alzheimer's in its sights

    The NervGen share has also not performed well in recent months. Unlike Valneva, however, it is not a vaccine that no one seems to want. NervGen is researching an active ingredient capable of activating the body's self-healing powers in cases of nerve damage. In trials with paraplegic mice, the active ingredient has already achieved impressive results. In addition to paralysis, NervGen is also targeting multiple sclerosis and Alzheimer's disease, addressing conditions that greatly affect the quality of life of both young and older people. Each advance alone would have blockbuster potential from the market's perspective. But why did the stock lose 25% over the past three months? NervGen is a growth company and is currently advancing its research. Such stocks have been particularly punished by the market recently. Some of the share price losses are therefore not attributable to events at the Company at all. In fact, NervGen has recently only been reporting on the status of its day-to-day business.

    NervGen CEO Bill Radvak recently outlined the Company's long-term outlook in an interview: "We intend to start our clinical trial with both recently injured and chronically injured patients. Studying a drug in patients who have been injured for more than a year is rare, but we have remarkable data suggesting that our drug can successfully help restore function in these patients too. We expect to see the results of these studies as early as next year, which is very exciting". NervGen is already seeking a listing on NASDAQ this year to broaden its investor base. Such a move has already given comparable companies a tailwind. Even if the market environment is currently not the friendliest, NervGen offers a promising growth perspective with its revolutionary approach. Should even a partial success be possible in the fight against MS or Alzheimer's, the share should also offer opportunities detached from the overall market.

    BioNTech: Overall market burdens even the industry leader

    BioNTech shows that even big names are currently floundering in no man's land. The Corona vaccine pioneer is well-positioned: The summer wave is shifting the focus back to the pandemic. In the fall, new vaccines are ready for the market that should also help against the new variants. In addition, the BioNTech team has emphasized that it wants to take off in the future around cancer and other diseases. This example shows that many promising plans are falling behind in the face of the overall market.


    Especially in difficult times on the stock market, investors with foresight can seize opportunities. Pfizer's entry into Valneva gives investors the signal that the development of promising vaccines and active ingredients will continue regardless of the day-to-day market noise. NervGen and BioNTech are also pushing ahead with their ambitious plans. If breakthroughs succeed, new potential should emerge.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Armin Schulz on June 17th, 2025 | 07:25 CEST

    Pharmaceutical revolution 2025: Why Novo Nordisk, NetraMark Holdings, and Bayer are doubling their returns through AI efficiency

    • Biotechnology
    • AI
    • Pharma

    The pharmaceutical industry is undergoing a digital transformation in 2025. Artificial intelligence is decoding active ingredients in record time, big data is driving personalized therapies, and blockchain is securing supply chains. These technologies are catapulting efficiency skyward and dramatically reducing development costs in a billion-dollar market that is growing steadily due to demographic change. Those who identify the right companies now will benefit from the disruptive wave. Therefore, we look at three companies that could benefit from this change: Novo Nordisk, NetraMark Holdings, and Bayer.

    Read

    Commented by André Will-Laudien on June 17th, 2025 | 07:05 CEST

    Takeovers! A new dawn for biotech companies – Evotec, BioNTech, PanGenomic Health, and CureVac in focus

    • healthtech
    • Biotechnology
    • Pharma

    Many large pharmaceutical companies are facing the "patent cliff" as patents on blockbuster drugs expire, threatening massive revenue losses in the future. To fill these gaps, they are acquiring suitable and innovative biotech companies with promising drug pipelines. Sometimes, however, they simply acquire technologies already worth billions. The current wave of acquisitions in the biotech sector is being driven by a combination of economic pressure, technological change toward AI and digitalization, and a weak financing environment for smaller biotech companies. After years of restraint and high volatility, fundamental valuation factors are back in focus. Investors are returning, creating a prosperous environment for those who jump on the bandwagon in time. We highlight a few ideas.

    Read

    Commented by Armin Schulz on June 16th, 2025 | 07:10 CEST

    Benefit from the biotech boom: Why Evotec, BioNxt Solutions & BioNTech could be the next winners

    • Biotechnology
    • Biotech
    • Pharma

    The biotech sector is pulsating with unique dynamism while traditional markets are faltering. The drivers are billion-dollar acquisitions, groundbreaking research, and strategic alliances. Large pharmaceutical companies are eagerly securing access to innovations. Analysts agree: strong patent portfolios and innovative partnerships are crucial for future growth. These protect valuable therapeutic developments and enable even smaller players to scale globally. For investors, this robust, capital-rich industry offers enormous opportunities. Those who identify the right innovators early on can reap above-average profits. Three companies embody this momentum: Evotec, BioNxt Solutions, and BioNTech.

    Read